Alphyn Biologics is a life science company that develops proprietary drug therapy for treating skin diseases.
Alphyn Biologics is a life science company that develops proprietary drug therapy for treating skin diseases. Alphyn's initial target indication are skin infections caused by deadly drug-resistant MRSA bacteria based on their proprietary Multi-Target Therapeutic (MTT) plant-derived technology platform.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 15, 2022 | Series A | $3.30M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Angel Physicians Fund | — | Series A |